SURVYR

OPCH

Option Care Health, Inc.
$31.29
+$0.06 (0.19%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-35%-18%-2%+15%+32%Oct 2025Oct 2026Apr 202652w high $36.8052w low $18.01
OPCHSPY
Wall St. Highest PT $33.00 (+5.5%) Wall St. Avg PT $30.03 (-4.0%)
$20$24$28$32$37POC $21Hi $33Avg $30
Underwater Drawdown %Max DD -46.7%Current -14.5%
0.0%-46.7%
Relative Strength vs SPY-1.1% vs SPYUnderperforming
+45%0%-45%
1W
−$0.07 (0.22%)
1M
+$8.22 (35.63%)
3M
+$8.81 (39.19%)
6M
+$3.52 (12.68%)
YTD
−$0.57 (1.79%)
1Y
+$3.45 (12.39%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
8 analysts · mean score 3.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$31.29
Average target$30.03
−$1.26 (−4.0%) downsideaverage target vs current price
CurrentAverageMedian
Low$23.00
Median$30.03
High$33.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$4.7B
P/E (last 12 months)23.7
P/E (next 12 months, estimated)15.0
52-week range$18.01 – $36.80
Revenue growth (latest quarter vs a year ago)+1.9%
Dividend yieldNo dividend
Analyst consensusHold (8)
Average analyst price target$30.03 (-4%)

What they do

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease.

Healthcare · Medical Care Facilities
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
19th percentile in sector
D
12-1 return: -13.6%
Percentile within its GICS sector across the S&P 1500.
Growth
17th percentile in sector
D
Revenue growth (YoY): +1.9%
Percentile within its GICS sector across the S&P 1500.
Value
62nd percentile in sector
B-
Forward E/P: 6.7% · EBITDA/EV: 7.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
50th percentile in sector
C+
Profit margin: +3.7% · Return on equity: +16.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

OPCH earningsNext report in 8 days
Next report
Wed Nov 4, 2026Before the open
EPS consensus$0.49
Revenue consensus–
Last 4 quarters · EPS vs estimate
Jul 29, 2026$0.45est $0.43+5.4%Above estimates
Apr 30, 2026$0.40est $0.37+8.1%Above estimates
Feb 24, 2026$0.46est $0.47−1.8%Below estimates
Oct 30, 2025$0.45est $0.43+4.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 18:11:07 ET
24-1025-0225-0425-0725-1026-0226-0426-070.000.47
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?
Zacks · Oct 07

Stats refreshed 2026-10-27 18:11:07 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026